Project Name：Ticagrelor 

Registration Classification：3+6

Formulations and specifications ：Tablets: 90mg 

Indications：For acute coronary syndrome ( unstable angina, non- ST -segment elevation myocardial infarction or ST -segment elevation myocardial infarction ) , including patients receiving drug therapy and percutaneous coronary intervention (PCI) treatment to reduce  the incidence of thrombotic cardiovascular events.

Original Research Company：AstraZeneca 

Progress ：Pharmaceutical Research in progress